Syntis Bio

Syntis Bio is developing oral therapies that leverage the small intestine’s therapeutic potential to treat obesity, diabetes, and rare diseases. Its lead product is an oral capsule that forms a transient barrier membrane in the intestine to suppress nutrient absorption—functioning as “bariatric surgery in a pill.” In addition, Syntis Bio is advancing two pipeline assets targeting gut-related orphan indications, expanding the potential of its novel platform.